CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, radiology oncologists, nurses, colorectal and general surgeons and other healthcare providers involved in the treatment of pancreatic cancer.
  
  LEARNING OBJECTIVES

  • Consider relevant biological, clinical and logistical factors in the selection of first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (PAD).
  • Appreciate recently published efficacy findings with nanoliposomal irinotecan (nal-IRI) as a component of first-line therapy for patients with metastatic PAD, and assess the potential role of this novel therapeutic strategy.
  • Develop an evidence-based treatment strategy for patients with metastatic PAD who experience disease progression on front-line chemotherapy, exploring the importance of age, performance status and prior therapeutic exposure.
  • Appraise available Phase III data leading to the FDA approval of olaparib maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings for clinical practice.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed for PAD to support quality of life and continuation of therapy.
  • Recall the biological rationale for and available and emerging data with other investigational agents currently in clinical testing for PAD, and refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.25 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form. Program location URLs are noted below:
  
  Audio Interview: ResearchToPractice.com/OncologyTodaymPancreatic23 and Educational Assessment and Credit Form ResearchToPractice.com/OncologyTodaymPancreatic23/CME.
  
  Video Interview: ResearchToPractice.com/OncologyTodaymPancreatic23/Video and Educational Assessment and Credit Form ResearchToPractice.com/OncologyTodaymPancreatic23/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Michael Pishvaian, MD, PhD
  Associate Professor, Department of Oncology
  Johns Hopkins University School of Medicine
  Washington, DC
  
  Advisory Committee: Astellas, TriSalus Life Sciences; Consulting Agreements: AstraZeneca Pharmaceuticals LP, IDEAYA Biosciences, Merck, Merus BV, Novartis, Pfizer Inc, Seagen Inc; Contracted Research: Amgen Inc, Arcus Biosciences, Astellas, BioMed Valley Discoveries, Boehringer Ingelheim Pharmaceuticals Inc, Hutchison MediPharma, IDEAYA Biosciences, Merck, Novartis, Pfizer Inc, RenovoRx, Repare Therapeutics, Seagen Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc; Nonrelevant Financial Relationship: Perthera (stock ownership).
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck, and Novocure Inc.
  
  Release date: October 2023
  Expiration date: October 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.